EUVIMEDEUVIMED entdecken
Crossref

Clinical Characteristics of inpatients with diabetes mellitus and Sodium/glucose Cotransporter-2 Inhibitors who then develop Euglycemic Ketoacidosis

Khan, Attiya, Ramanathan, Jay, Wong, Vincent, Namson S. Lau

UNSWorks (University of New South Wales, Sydney, Australia) · 06.08.2025

DOI: 10.26190/unsworks/31422 ↗

Kurz gefasst

Fachartikel in der Zeitschrift UNSWorks (University of New South Wales, Sydney, Australia), erschienen am 06.08.2025. Verfasst von Khan und 6 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are a novel class of oral agents with glucose lowering effect and reno- and cardio-protection increasingly used to treat type 2 diabetes mellitus (T2DM). Patients with T2DM on SGLT2i are at increased risk of diabetic ketoacidosis with normal blood glucose levels, called euglycemic ketoacidosis (eDKA). Not all patients taking SGLT2i develop this side effect; it is important to look at potential patient and other factors in those who develop eDKA to better understand this potentially severe complication.

Methods

We are conducting a cohort analysis of inpatients with T2DM admitted to a large metropolitan university teaching hospital (Liverpool, NSW). Patient factors of demographics, clinical details leading to hospital admission, other medical co-morbidities, duration and control of diabetes, and will be measured. Measured eDKA factors are: time of last SGLT2i use, when eDKA developed, voluntary or involuntary fasting, duration of fast, blood glucose & blood ketone levels, and pH, renal function, and actions to treat eDKA. Discharge information will include whether SGLT2i therapy was resumed, and follow-up plans.

Results

Between 2020-21, 15 cases of eDKA were reported and are being analysed; since January this year, 10 eDKA cases have been reported and are being analysed. Further cases will be added to the final ePoster.

Conclusions

Greater knowledge about the clinical characteristics of eDKA cases can help aid design of mitigation strategies.

Schlagwörter

euglycemic diabetic ketoacidosisSGLT2 inhibitorstype 2 diabetesadverse drug reactionshospitalized patientsfastingketone levelsrenal functionrisk factors

Zitieren

APA

Khan, Attiya, Ramanathan, Jay, Wong, Vincent, & Lau, N. S. (2025). Clinical Characteristics of inpatients with diabetes mellitus and Sodium/glucose Cotransporter-2 Inhibitors who then develop Euglycemic Ketoacidosis. UNSWorks (University of New South Wales, Sydney, Australia). https://doi.org/10.26190/unsworks/31422

Vancouver

Khan, Attiya, Ramanathan, Jay, Wong, Vincent, et al. Clinical Characteristics of inpatients with diabetes mellitus and Sodium/glucose Cotransporter-2 Inhibitors who then develop Euglycemic Ketoacidosis. UNSWorks (University of New South Wales, Sydney, Australia). 2025. doi:10.26190/unsworks/31422

BibTeX
@article{Khan2025,
  author = {Khan and Attiya and Ramanathan and Jay and Wong and Vincent and Lau, Namson S.},
  title = {Clinical Characteristics of inpatients with diabetes mellitus and Sodium/glucose Cotransporter-2 Inhibitors who then develop Euglycemic Ketoacidosis},
  journal = {UNSWorks (University of New South Wales, Sydney, Australia)},
  year = {2025},
  doi = {10.26190/unsworks/31422}
}
Kostenlos starten →